CD160 Antibody

Product Specifications

Background

CD160, also known as BY55, is a lipid-anchored cell membrane glycoprotein that contains one immunoglobulin-like domain (1) . It is expressed in small intestine, spleen and functional NK and T cytotoxic lymphocytes (1,2) . CD160 exists as a disulfide-linked homomultimer that functions as a receptor for MHC (major histocompatability complex) molecules and is thought to regulate the function of NK cells (2,3) . Additionally, CD160 interacts with TNFRSF14 and, via this interaction, is able to negatively regulate CD4+ T cell activation, indicating a role in immune system regulation (4) .

NCBI Gene ID

11126

Swiss Prot

O95971

Accession Number

NP_008984

Host

Rabbit

Reactivity

Human, Mouse

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Immunology

Purification

CD160 Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1204 - K562 Cell Lysate

Concentration

1 mg/mL

Buffer

CD160 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

CD160 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

CD160 antibody is human and mouse reactive. Multiple isoforms of CD160 are known to exist.

Symbol

CD160

NCBI Official Name

CD160 molecule

NCBI Organism

Homo sapiens

Background Reference 01

Anumanthan A, Bensussan A, Boumsell L, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J. Immunol. 1998; 161:2780-90.

Background Reference 02

Agrawal S, Marquet J, Freeman GJ, et al. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J. Immunol. 1999; 162:1223-6.

Background Reference 03

Le Bouteiller P, Tabiasco J, Polgar B, et al. CD160: a unique activating NK cell receptor. Immunol. Lett. 2011;138:93-6

Background Reference 04

Chabot S, Jabrane-Ferrat N, Bigot K, et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J. Exp. Med. 2011; 208:973-86.